Trend Report

Optimising the Pharmaceutical Packaging Supply Chain with Dual Sourcing

Why dual sourcing for pharmaceutical packaging components has evolved from a contingency measure into a strategic necessity — and how to implement it effectively across the drug lifecycle.

Status Published

Format Trend Report

Language English

Access Registration Required

Read the Report

Resource Overview

About this Trend Report

In an era of interconnected supply chains, trade tensions, pandemic demand shocks, and accelerating regulatory change, single-source dependency for pharmaceutical packaging components represents an unacceptable business risk. This 2025 report by Datwyler draws on GlobalData survey data — which ranked supply chain challenges among the top industry concerns for 2025 alongside anti-obesity medications and AI — to build the case for dual sourcing as a foundational element of pharmaceutical packaging strategy.

The report explains how dual sourcing delivers benefits beyond crisis insurance: greater negotiating power, faster access to innovation, fill/finish line flexibility, and the ability to absorb regulatory changes without supply interruption. A particularly important strategic insight is the recommendation to diversify materials within a dual sourcing strategy — not simply replicate the same component from two suppliers — as illustrated by the PFAS regulatory risk scenario, where pairing a film-coated closure with Datwyler's NFS-grade spray-coated OmniFlex® or NeoFlex™ alternative provides a hedge regardless of how regulations evolve. The report also details Datwyler's OmniFlex®/NeoFlex™ platform approach to lifecycle consistency — enabling seamless transitions from vial to prefilled syringe to cartridge using the same elastomer formulation and fluoropolymer coating — and highlights the advantage of Datwyler's globally harmonized FirstLine® manufacturing network for local-for-local supply resilience.

Single-sourcing pharmaceutical packaging creates a critical point of failure that geopolitical disruption, quality events, or demand surges can expose at any time — as demonstrated during the COVID-19 pandemic, when companies with pre-qualified alternate components maintained production while others faced costly delays.
The most resilient dual sourcing strategies deliberately incorporate differentiated materials rather than identical components from two suppliers, using technology diversity — such as pairing film-coated closures with spray-coated alternatives — to hedge against regulatory changes like PFAS restrictions that could simultaneously render two identical components non-compliant.
Implementing dual sourcing from the beginning of drug development, as part of the CMC strategy, is the most cost-effective approach: qualifying two components through extractables/leachables, compatibility, stability, and machinability testing upfront eliminates expensive late-stage revalidation and gives pharmaceutical manufacturers a robust, audit-ready supply chain platform for the full drug lifecycle.

Optimising the Pharmaceutical Packaging Supply Chain with Dual Sourcing

About this Trend Report

Download the White Paper

More Supply Chain Resilience Resources

FirstLine®: Datwyler's Most Advanced Manufacturing Standard

Strengthening Your Supply Chain: The Power of Dual Sourcing Pharmaceutical Packaging

Assurance in Injectable Drug Packaging: A Strategic Checklist for Aluminum Component Compatibility, Compliance, and Continuity

Stay informed on Datwyler Healthcare technical resources